Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Follow-up of Oxytocin in PWS
NCT05032326Phase 3Recruiting
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Sep 2021
- Primary completion
- Apr 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, open-label trial of oxytocin in Prader-Willi syndrome (PWS) (2 cohorts), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Confirmation of the long term safety profile at 4 years. Started Sep 2021; status: recruiting.
02
Drugs
oxytocin
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on NCT05032326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05032326.